Genflow Biosciences and CER Sign Master Service Agreement to Strengthen Long-Term R&D Collaboration
Genflow Biosciences (OTCQB:GENFF), Europe's only publicly listed longevity company, has signed a Master Service Agreement (MSA) with CER Groupe, a private Belgian research center. The agreement formalizes their existing partnership and establishes a framework for accelerating Genflow's pre-IND gene therapy programs. The collaboration will focus on developing, producing, and characterizing gene therapy candidates while implementing standardized project management systems. CER Groupe brings ISO and GxP-compliant facilities and integrated bioproduction and pre-clinical services to the partnership.
Genflow Biosciences (OTCQB:GENFF), l'unica società europea quotata in borsa nel settore della longevità, ha firmato un Master Service Agreement (MSA) con CER Groupe, un centro di ricerca privato belga. L'accordo formalizza la collaborazione già esistente e crea un quadro per accelerare i programmi di terapia genica pre-IND di Genflow. La partnership si concentrerà sullo sviluppo, la produzione e la caratterizzazione dei candidati per la terapia genica, implementando sistemi standardizzati di gestione dei progetti. CER Groupe offre strutture conformi agli standard ISO e GxP, oltre a servizi integrati di bioproduzione e preclinici.
Genflow Biosciences (OTCQB:GENFF), la única empresa europea de longevidad que cotiza en bolsa, ha firmado un Acuerdo Marco de Servicios (MSA) con CER Groupe, un centro de investigación privado belga. El acuerdo formaliza su colaboración existente y establece un marco para acelerar los programas de terapia génica pre-IND de Genflow. La colaboración se centrará en el desarrollo, producción y caracterización de candidatos para terapia génica, implementando sistemas estandarizados de gestión de proyectos. CER Groupe aporta instalaciones certificadas ISO y GxP, además de servicios integrados de bioproducción y preclínicos a la asociación.
Genflow Biosciences (OTCQB:GENFF)는 유럽에서 유일하게 상장된 장수명 연구 기업으로, 벨기에의 민간 연구 센터인 CER Groupe와 주요 서비스 계약(MSA)을 체결했습니다. 이 계약은 기존 파트너십을 공식화하고 Genflow의 IND 이전 유전자 치료 프로그램 가속화를 위한 틀을 마련합니다. 협력은 유전자 치료 후보물질의 개발, 생산 및 특성 분석에 집중하며, 표준화된 프로젝트 관리 시스템을 도입할 예정입니다. CER Groupe는 ISO 및 GxP 규격에 부합하는 시설과 통합된 생물생산 및 전임상 서비스를 제공합니다.
Genflow Biosciences (OTCQB:GENFF), la seule société européenne cotée en bourse spécialisée dans la longévité, a signé un Master Service Agreement (MSA) avec CER Groupe, un centre de recherche privé belge. Cet accord formalise leur partenariat existant et établit un cadre pour accélérer les programmes de thérapie génique pré-IND de Genflow. La collaboration se concentrera sur le développement, la production et la caractérisation des candidats en thérapie génique, tout en mettant en place des systèmes standardisés de gestion de projet. CER Groupe apporte des installations conformes aux normes ISO et GxP ainsi que des services intégrés de bioproduction et de préclinique à ce partenariat.
Genflow Biosciences (OTCQB:GENFF), Europas einzig börsennotiertes Longevity-Unternehmen, hat eine Master Service Agreement (MSA) mit CER Groupe, einem privaten belgischen Forschungszentrum, unterzeichnet. Die Vereinbarung formalisiert ihre bestehende Partnerschaft und schafft einen Rahmen zur Beschleunigung von Genflows prä-IND Gentherapieprogrammen. Die Zusammenarbeit konzentriert sich auf die Entwicklung, Produktion und Charakterisierung von Gentherapiekandidaten unter Implementierung standardisierter Projektmanagementsysteme. CER Groupe bringt ISO- und GxP-konforme Einrichtungen sowie integrierte Bioproduktions- und präklinische Dienstleistungen in die Partnerschaft ein.
- None.
- None.
LONDON, UK / ACCESS Newswire / May 28, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, is pleased to announce the signing of a Master Service Agreement (MSA) with CER Groupe (CER), a long-standing partner of the Company.
CER is a private Belgian research center offering integrated bioproduction and pre-clinical services within a regulated ISO and GxP-compliant environment. The MSA formalizes the working relationship between Genflow and CER, providing a robust R&D framework to accelerate Genflow's pre-IND gene therapy programs.
Under the terms of the MSA, Genflow and CER will:
Develop, produce and characterize Genflow's gene therapy candidates;
Implement a collaborative project management system to drive efficient execution and timely deliverables supporting Genflow's goals with standardized templates for Task Orders and technical services; and
Combine scientific expertise derisks, innovate and ensure relevant scientific outcomes.
Said Dr. Eric Leire, CEO of Genflow: "Our partnership with CER has been instrumental in supporting our R&D efforts to date. Formalizing this collaboration through the MSA will enable greater operational alignment and strategic agility as we continue to accelerate our pipeline."
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
Corporate Brokers | |
Capital Plus Partners Ltd | |
Jon Critchley, +44 0203 821 6168 |
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments.
Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
About CER Groupe
CER Groupe is a GLP-certified private Belgian research center supporting European life sciences innovation for more than 45years. CER's 200 colleagues gather cutting-edge expertise ensuring high quality integrated bioproduction and non-clinical services. CER supports companies in progressing their development from idea generation up to IND-enabling studies. CER Groupe favors collaborative and agile approaches accelerating companies' access to clinical stage development.
Visit www.cergroupe.be to learn what CER's partners say and follow CER Groupe on LinkedIn to stay up-to-date on CER's latest developments.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
What is the purpose of the Master Service Agreement between Genflow Biosciences (GENFF) and CER Groupe?
What services will CER Groupe provide to Genflow Biosciences (GENFF)?
Who is the CEO of Genflow Biosciences (GENFF)?
What makes Genflow Biosciences (GENFF) unique in Europe?
